Pérdida de Grasa y Composición Corporal

Cagrilintida / Semaglutida

$650.00

Per vial
$65.00
10 vials per pack
Suggested retail
$195.00
3× markup · per vial
Envío gratuito en pedidos superiores a $2,000
$300 store credit on any independent COA · results don't matter
  • Garantía de entrega Reenvío gratuito si no llega
  • Pureza ≥99 % Producción directa del fabricante
  • Certificados de análisis independientes Ver certificados de análisis de este producto →
  • Garantía de crédito en tienda Envía cualquier resultado de COA y obtén crédito en la tienda

CagriSema - Cagrilintide / Semaglutide Combination Research Peptide

CagriSema is the co-formulated research blend of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), both developed by Novo Nordisk. It is the first once-weekly combination of a GLP-1 and an amylin analog and is the subject of the REDEFINE 1 and REDEFINE 2 Phase 3 trial programs. The two peptides act through non-overlapping signaling pathways, which is why researchers pair them in a single vial instead of running parallel single-peptide studies.


Why Pair Cagrilintide with Semaglutide

Semaglutide (the peptide behind Ozempic and Wegovy) targets the GLP-1 receptor - an incretin pathway that amplifies insulin release and slows gastric emptying. Cagrilintide targets the amylin receptor - a parallel pathway in the brainstem and hypothalamus that regulates meal size and satiety. Because the two pathways don’t overlap, the combined signal is larger than either alone, and each peptide complements what the other does not cover.

Péptido Receptor class En pocas palabras, esto es lo que hace
Cagrilintide Amylin analog Regulates meal size and satiety through brainstem amylin receptors
Semaglutide GLP-1 receptor agonist Amplifies insulin release, slows gastric emptying, reduces glucagon

CagriSema vs Semaglutide vs Tirzepatide

These three show up in most current metabolic-research literature, so the distinction matters.

Compuesto Mechanism class Frequency
CagriSema Amylin + GLP-1 (dual, paired) Once weekly, co-formulated
Semaglutide GLP-1 agonist (single mechanism) Once weekly
Tirzepatide GLP-1 + GIP (single molecule) Once weekly

CagriSema and tirzepatide are both “dual-mechanism” compounds, but they hit different pairs: CagriSema is amylin + GLP-1, tirzepatide is GIP + GLP-1. The SURMOUNT and REDEFINE trial programs characterize each pairing independently.


Aplicaciones de investigación

CagriSema is used in studies examining:

  • Combined amylin + GLP-1 signaling in a single administration
  • Body-composition endpoints under dual-pathway stimulation
  • Ad-libitum caloric-intake and satiety modeling
  • Glycemic and blood-pressure markers in Phase 3 protocol replication (REDEFINE framework)
  • Comparative research vs. GLP-1 monotherapy and vs. GIP/GLP-1 dual agonists

Especificaciones

Formato Lyophilized powder, both peptides co-lyophilized
Pureza ≥99% each peptide
Alias CagriSema, cagrilintide/semaglutide, amylin + GLP-1 blend
Tamaños disponibles 5mg cagrilintide + 5mg semaglutide
Almacenamiento 2-8 °C sin abrir; estable durante más de 12 meses
Uso Research purposes only - not for human use

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for Cagrilintide / Semaglutide are documented in the published peer-reviewed literature and standard peptide-chemistry references.


Reference Literature

Published clinical and preclinical Cagrilintide / Semaglutide literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.


Common Questions About CagriSema Research

How is CagriSema different from semaglutide alone?

CagriSema adds cagrilintide (an amylin analog) to semaglutide. Semaglutide on its own works through a single pathway (GLP-1). CagriSema works through two non-overlapping pathways (amylin + GLP-1), which is why the combined trial endpoints are larger than semaglutide monotherapy endpoints.

Is CagriSema a GLP-1?

It contains one. CagriSema is a combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analog). It is not a single peptide - it is two peptides co-formulated in one vial.

How does CagriSema compare to tirzepatide?

They are both dual-mechanism compounds but hit different receptor pairs. CagriSema pairs an amylin analog with a GLP-1 agonist. Tirzepatide is a single molecule that activates GLP-1 and GIP. A head-to-head trial (Novo Nordisk’s REDEFINE 4 / Eli Lilly’s SURMOUNT-5 framework) has been the subject of ongoing comparative research.

Is CagriSema FDA approved?

Novo Nordisk has filed for FDA approval of CagriSema (2026). At the time of writing it is not approved for any human use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is the blend stored?

Los viales sin abrir se conservan a una temperatura de entre 2 y 8 °C y se mantienen estables durante más de 12 meses. Una vez reconstituida con agua bacteriostática, la solución se conserva a una temperatura de entre 2 y 8 °C y debe utilizarse en un plazo de 28 a 30 días.


Garantía de pureza

Cada lote tiene una pureza ≥99 %. Envíanos un certificado de análisis (COA) de cualquier análisis independiente y te daremos un vale de compra, independientemente de lo que indique.